However, the challenge of TRAIL resistance in some cancer cells persists, prompting clinical trials 84 that explore overcoming this resistance through combination therapies with natural products or synthetic drugs such as disipramine, liensinine, and glipizide, aiming to sensitize these resistant tumor cells to TRAIL-induced apoptosis 87, 92-94. Here, TNFSF10 is linked to neoplasm.